Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Part D Formularies May Omit Lexapro Or Celexa, CMS Says

Executive Summary

Medicare Part D plans will not be required to include both Forest antidepressants Lexapro and Celexa in their formularies, the Centers for Medicare & Medicaid Services said in a supplement to a question and answer document on the program

You may also be interested in...



2008 Deals Of The Year

Each week, "The Pink Sheet" presents commentary on some of the most interesting new business deals, contributed by the editors of the IN VIVO blog. As 2008 came to a close, the editors nominated the following transactions as their top deals of the year. Feeling moved to weigh in with your own favorite? 1Full write-ups of each deal and IVB's poll can be found at: http://invivoblog.blogspot.com/search/label/DOTY

AHRQ Antidepressant Report May Put Pressure On CMS Formulary Guidelines

An Agency for Healthcare Research & Quality draft report finding no substantial efficacy difference among second-generation antidepressants could increase pressure on CMS' "all or substantially all" coverage policy for the class

AHRQ Antidepressant Report May Put Pressure On CMS Formulary Guidelines

An Agency for Healthcare Research & Quality draft report finding no substantial efficacy difference among second-generation antidepressants could increase pressure on CMS' "all or substantially all" coverage policy for the class

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045962

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel